Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, 5-FU, and Radiation in Locally Advanced Pancreatic Cancer
NCT00026130Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2001
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival at 3 years. Started Sep 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00026130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026130.